Weill Medical College of Cornell University, New York, New York, USA.
Department of Neurosurgery, Weill Medical College of Cornell University, New York, New York, USA.
World Neurosurg. 2019 Jul;127:397-404. doi: 10.1016/j.wneu.2019.04.093. Epub 2019 Apr 17.
Checkpoint immunotherapy (CIT) is an emerging and exciting treatment modality for the treatment of cancer. Much excitement has ensued in the potential of CIT to revolutionize the treatment and prognosis of brain metastases. The combination of stereotactic radiosurgery (SRS) and CIT has also been studied and showed promise compared with either treatment modality alone. However, several questions have arisen, in particular, the timing at which SRS and CIT should be administered relative to each other. We reviewed the reported data and attempted to offer a potential answer to this question.
检查点免疫疗法（CIT）是一种新兴的、令人兴奋的癌症治疗方法。CIT 有可能彻底改变脑转移瘤的治疗和预后，这引起了广泛的关注。立体定向放射外科（SRS）和 CIT 的联合应用也已经进行了研究，并显示出与单一治疗方法相比有更好的前景。然而，出现了一些问题，特别是 SRS 和 CIT 相互之间的给药时机。我们回顾了已报道的数据，并试图对此问题提供一个可能的答案。
